What Are Senolytics? Zombie Cells and Longevity, Explained

Senolytics are one of the most talked-about ideas in longevity science: a class of compounds designed to clear out worn-out "zombie" cells that accumulate with age. They're a genuinely interesting area of research — and understanding them also clarifies what urolithin A is not.

What senolytics are

Senolytics are compounds under investigation for their ability to selectively trigger the death of senescent cells — aged or damaged cells that have stopped dividing but refuse to die off cleanly. The word itself is a clue: "seno" for senescence, "lytic" for breaking apart. The hypothesis is that by removing these cells, you reduce a source of chronic, low-grade stress in tissues and, in principle, support healthier aging. It's important to say at the outset that senolytics remain a research category. Most are studied in cells and animals, a few have reached early human trials, and none is an established, approved anti-aging therapy.

First, what is a senescent cell?

As cells divide over a lifetime, some reach a point — through DNA damage, telomere shortening, or other stress — where they permanently stop dividing. This state is called cellular senescence, and it isn't all bad: it's partly a safety brake that stops damaged cells from becoming cancerous, and it plays a role in wound healing. The problem is that senescent cells don't always get cleared away. They linger. Our article on cellular senescence goes deeper, but the short version is that these cells become a kind of metabolic squatter.

What makes lingering senescent cells troublesome is that they are not inert. Many of them secrete a cocktail of inflammatory signals, growth factors, and enzymes known as the senescence-associated secretory phenotype, or SASP. Through the SASP, a relatively small number of senescent cells can spread stress signals to healthy neighbors, which is why they're sometimes nicknamed "zombie cells." The accumulation of senescent cells and their SASP is one of the recognized hallmarks of aging.

How senolytics are supposed to work

Senescent cells survive, in part, by switching on "pro-survival" defenses that block their own self-destruction (apoptosis). Senolytics are designed to disable those defenses so the senescent cell finally undergoes the programmed death it has been resisting — while, ideally, leaving healthy cells untouched. The selectivity is the hard part and the central challenge of the field.

A few specific candidates come up repeatedly in the literature:

Dasatinib + quercetin (D+Q)

This pairing — a repurposed cancer drug combined with the plant flavonoid quercetin — is the most-studied senolytic combination. It has human cell, mouse, and early (phase I) human trial data. The flavonoid quercetin on its own is also studied for other properties; you can read about it in our overview of quercetin.

Fisetin

Fisetin is another plant flavonoid studied as a senolytic, mostly in cell and animal models, with human trials in progress. See our guide to fisetin for more.

Navitoclax and others

Navitoclax is an experimental small molecule that blocks specific pro-survival proteins; it and several other candidates remain largely preclinical.

Researchers also distinguish senolytics from two related ideas. Senomorphics (such as apigenin or rapamycin) don't kill senescent cells — they quiet the SASP. Senostatics (metformin is a commonly cited example) aim to slow cells from becoming senescent in the first place. All three are active areas of study.

Where the evidence actually stands

This is where honesty matters. The most eye-catching senolytic results — animals living healthier and in some studies longer, tissues looking "younger" after senescent cells are cleared — come overwhelmingly from preclinical research in mice and cells. These findings are exciting and have driven a wave of human trials, but animal results have a long history of not translating neatly to people. Human senolytic data remains early-stage and limited, often from small phase I safety studies rather than large trials showing clear clinical benefit. Anyone describing senolytics as a proven way to slow human aging is getting ahead of the evidence.

How urolithin A is different — and why that matters

It's easy to lump every longevity compound together, so this distinction is worth drawing clearly: urolithin A is not a senolytic. They target different problems through different mechanisms.

A senolytic tries to remove whole cells that have gone senescent. Urolithin A, by contrast, is studied for mitophagy — the housekeeping process by which a living, healthy cell identifies its own worn-out mitochondria and recycles them, making room for fresh ones. One approach clears out bad cells; the other helps good cells maintain the power plants inside them. You can read how that recycling works in our explainer on mitophagy.

This difference also shows up in the quality of the evidence. Urolithin A's mitophagy story rests on a foundational 2016 Nature Medicine paper by Ryu and colleagues — which was preclinical, showing improved mitophagy and muscle function in rodents and extended lifespan in C. elegans — followed by a series of randomized, placebo-controlled human trials. A 2019 first-in-human study in Nature Metabolism (Andreux et al.) found urolithin A safe and well tolerated and showed it induced a mitochondrial gene-expression signature. Later human trials, including Singh et al. 2022 in Cell Reports Medicine and a 2022 study in JAMA Network Open, reported effects on muscle endurance and strength in middle-aged and older adults. In other words, urolithin A has crossed from animal models into repeated human testing on muscle and mitochondrial endpoints — a step most senolytic candidates have not yet firmly made.

Should you take a senolytic?

That's a question for you and a qualified healthcare provider, not a blog page — and especially not for the prescription-derived candidates like dasatinib, which carry real pharmacology and are not supplements. The flavonoids studied as senolytics, such as quercetin and fisetin, are sold as supplements, but the senolytic dosing and intermittent protocols explored in research are not established for general use, and interactions and individual health factors are genuine considerations. None of this is a treatment for any disease.

If your interest is simply supporting healthy aging with something that has human evidence behind it, urolithin A is a more mature option, which is why we focus on it. For a sense of how it compares to other popular longevity ingredients, see urolithin A vs fisetin and our best urolithin A gummies comparison.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.